Native thrombopoietin: Structure and function

Takashi Kato, Atsushi Matsumoto, Kinya Ogami, Tomoyuki Tahara, Haruhiko Morita, Hiroshi Miyazaki

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Thrombopoietin (TPO), the c-Mpl ligand, is produced constitutively in liver and other organs, circulates in the bloodstream, and is delivered to bone marrow, where it stimulates the early development of multiple hematopoietic lineages and megakaryocytopoiesis. The concentration of TPO in blood is regulated by c-Mpl mass on platelets and megakaryocytes. In addition to regulation by the number of TPO molecules, including the possible modulation of TPO mRNA abundance in bone marrow, megakaryocytopoiesis and platelet production may be regulated as a result of modulation of TPO activity by proteolytic processing that generates truncated forms of the molecule. Characterization of TPO partially purified from human plasma, however, revealed that the full-length molecule was the predominant form in the blood of both normal individuals and thrombocytopenic patients, although small amounts of truncated species were detected. Thus, truncation of TPO, at least that in the circulation examined, does not appear to contribute to the direct regulation of platelet production in response to increased demand. Given that native TPO isolated from the plasma of thrombocytopenic animals comprises truncated forms, the truncation of TPO is likely of physiological importance in the life history of this molecule.

Original languageEnglish
Pages (from-to)322-328
Number of pages7
JournalStem Cells
Volume16
Issue number5
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Thrombopoietin
Thrombopoiesis
Blood Platelets
Bone Marrow
Megakaryocytes

Keywords

  • ELISA
  • Native thrombopoietin
  • Posttranslational processing
  • Proteolysis
  • Thrombocytopenia
  • Thrombopoietin
  • Truncation

ASJC Scopus subject areas

  • Cell Biology

Cite this

Kato, T., Matsumoto, A., Ogami, K., Tahara, T., Morita, H., & Miyazaki, H. (1998). Native thrombopoietin: Structure and function. Stem Cells, 16(5), 322-328.

Native thrombopoietin : Structure and function. / Kato, Takashi; Matsumoto, Atsushi; Ogami, Kinya; Tahara, Tomoyuki; Morita, Haruhiko; Miyazaki, Hiroshi.

In: Stem Cells, Vol. 16, No. 5, 1998, p. 322-328.

Research output: Contribution to journalArticle

Kato, T, Matsumoto, A, Ogami, K, Tahara, T, Morita, H & Miyazaki, H 1998, 'Native thrombopoietin: Structure and function', Stem Cells, vol. 16, no. 5, pp. 322-328.
Kato T, Matsumoto A, Ogami K, Tahara T, Morita H, Miyazaki H. Native thrombopoietin: Structure and function. Stem Cells. 1998;16(5):322-328.
Kato, Takashi ; Matsumoto, Atsushi ; Ogami, Kinya ; Tahara, Tomoyuki ; Morita, Haruhiko ; Miyazaki, Hiroshi. / Native thrombopoietin : Structure and function. In: Stem Cells. 1998 ; Vol. 16, No. 5. pp. 322-328.
@article{8a44b71bcc474a1a8c00f91fb0e7ebdd,
title = "Native thrombopoietin: Structure and function",
abstract = "Thrombopoietin (TPO), the c-Mpl ligand, is produced constitutively in liver and other organs, circulates in the bloodstream, and is delivered to bone marrow, where it stimulates the early development of multiple hematopoietic lineages and megakaryocytopoiesis. The concentration of TPO in blood is regulated by c-Mpl mass on platelets and megakaryocytes. In addition to regulation by the number of TPO molecules, including the possible modulation of TPO mRNA abundance in bone marrow, megakaryocytopoiesis and platelet production may be regulated as a result of modulation of TPO activity by proteolytic processing that generates truncated forms of the molecule. Characterization of TPO partially purified from human plasma, however, revealed that the full-length molecule was the predominant form in the blood of both normal individuals and thrombocytopenic patients, although small amounts of truncated species were detected. Thus, truncation of TPO, at least that in the circulation examined, does not appear to contribute to the direct regulation of platelet production in response to increased demand. Given that native TPO isolated from the plasma of thrombocytopenic animals comprises truncated forms, the truncation of TPO is likely of physiological importance in the life history of this molecule.",
keywords = "ELISA, Native thrombopoietin, Posttranslational processing, Proteolysis, Thrombocytopenia, Thrombopoietin, Truncation",
author = "Takashi Kato and Atsushi Matsumoto and Kinya Ogami and Tomoyuki Tahara and Haruhiko Morita and Hiroshi Miyazaki",
year = "1998",
language = "English",
volume = "16",
pages = "322--328",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "5",

}

TY - JOUR

T1 - Native thrombopoietin

T2 - Structure and function

AU - Kato, Takashi

AU - Matsumoto, Atsushi

AU - Ogami, Kinya

AU - Tahara, Tomoyuki

AU - Morita, Haruhiko

AU - Miyazaki, Hiroshi

PY - 1998

Y1 - 1998

N2 - Thrombopoietin (TPO), the c-Mpl ligand, is produced constitutively in liver and other organs, circulates in the bloodstream, and is delivered to bone marrow, where it stimulates the early development of multiple hematopoietic lineages and megakaryocytopoiesis. The concentration of TPO in blood is regulated by c-Mpl mass on platelets and megakaryocytes. In addition to regulation by the number of TPO molecules, including the possible modulation of TPO mRNA abundance in bone marrow, megakaryocytopoiesis and platelet production may be regulated as a result of modulation of TPO activity by proteolytic processing that generates truncated forms of the molecule. Characterization of TPO partially purified from human plasma, however, revealed that the full-length molecule was the predominant form in the blood of both normal individuals and thrombocytopenic patients, although small amounts of truncated species were detected. Thus, truncation of TPO, at least that in the circulation examined, does not appear to contribute to the direct regulation of platelet production in response to increased demand. Given that native TPO isolated from the plasma of thrombocytopenic animals comprises truncated forms, the truncation of TPO is likely of physiological importance in the life history of this molecule.

AB - Thrombopoietin (TPO), the c-Mpl ligand, is produced constitutively in liver and other organs, circulates in the bloodstream, and is delivered to bone marrow, where it stimulates the early development of multiple hematopoietic lineages and megakaryocytopoiesis. The concentration of TPO in blood is regulated by c-Mpl mass on platelets and megakaryocytes. In addition to regulation by the number of TPO molecules, including the possible modulation of TPO mRNA abundance in bone marrow, megakaryocytopoiesis and platelet production may be regulated as a result of modulation of TPO activity by proteolytic processing that generates truncated forms of the molecule. Characterization of TPO partially purified from human plasma, however, revealed that the full-length molecule was the predominant form in the blood of both normal individuals and thrombocytopenic patients, although small amounts of truncated species were detected. Thus, truncation of TPO, at least that in the circulation examined, does not appear to contribute to the direct regulation of platelet production in response to increased demand. Given that native TPO isolated from the plasma of thrombocytopenic animals comprises truncated forms, the truncation of TPO is likely of physiological importance in the life history of this molecule.

KW - ELISA

KW - Native thrombopoietin

KW - Posttranslational processing

KW - Proteolysis

KW - Thrombocytopenia

KW - Thrombopoietin

KW - Truncation

UR - http://www.scopus.com/inward/record.url?scp=0031691754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031691754&partnerID=8YFLogxK

M3 - Article

C2 - 9766811

AN - SCOPUS:0031691754

VL - 16

SP - 322

EP - 328

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 5

ER -